How do you choose between Atezolizumab/Bevacizumab (IMbrave 150) versus Durvalumab/Tremelimumab (HIMALAYA) versus Ipilimumab/Nivolumab (Checkmate09DW) in first-line metastatic hepatocellular cancer?

For patients suitable for both regimens, how does the dosing frequency of HIMALAYA (single dose treme + Q4W durva) vs IMBrave150 (Q3W atezo/bev) impact your choice?

• The dosing frequency has no impact on my choice between regimens
• I am more inclined to prescribe HIMALAYA due to less frequent dosing of durva (Q4W) vs. atezo (Q3W)
• I am more inclined to prescribe HIMALAYA due to ability to remain on durva monotherapy following single dose of treme
• I am more inclined to prescribe HIMALAYA for both of the reasons cited above
• I am more inclined to prescribe IMBrave150 due to simplicity of Q3W regimen vs. single dose treme + Q4W durva
• Other